Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof
The present invention relates to methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof. In particular, the present invention relates to a method for performing antisense oligonucleotide-mediated exon skipping in a retina cell of a subject comprising the step of injecting into the vitreous of the subject an amount of the antisense oligonucleotide.
1. A method for performing antisense oligonucleotide-mediated exon skipping of a gene encoding ABCA4 in a photoreceptor cell of a subject in need thereof comprising the step of injecting into the vitreous of the subject an amount of a naked antisense oligonucleotide targeting the gene encoding ABCA4, wherein the subject suffers from Stargardt disease caused by a mutation which modifies the splicing and/or creates a premature termination in the ABCA4 gene important to the functioning and/or the survival of the photoreceptor cell, wherein the antisense oligonucleotide comprises a sequence that is complementary to a splice donor site, splice acceptor site, or a branch site within the pre-mRNA of the ABCA4 gene, wherein the naked antisense oligonucleotide performs antisense oligonucleotide-mediated exon skipping in the pre-mRNA from the ABCA4 gene which mutation causes Stargardt disease, in the nucleus of the photoreceptor cell of the subject, and wherein the antisense oligonucleotide is chronically administered by intravitreal injections at least 10 days apart.
2. The method of claim 1 wherein the naked antisense oligonucleotide is selected from the group consisting of oligodeoxyribonucleotides, oligoribonucleotides, Locked Nucleic Acid (LNA) oligonucleotides, morpholinos oligonucleotides, tricyclo-DNA-antisense oligonucleotides, U7- or U1-mediated antisense oligonucleotides, peptide-conjugated, nanoparticle-complexed antisense oligonucleotides, 2′-O-Me RNA/ENA chimera oligonucleotides, and 2′-O-methyl-phosphorothioate oligonucleotides.
3. The method of claim 1 , wherein the antisense oligonucleotide is 10-50 nucleotides in length.
4. The method of claim 1 , wherein the antisense oligonucleotide is chronically administered by intravitreal injections at least one month apart.
5. A method of treating Stargardt disease caused by a mutation which modifies the splicing and/or creates a premature termination in the ABCA4 gene, important to the functioning and/or the survival of a photoreceptor cell, in a subject in need thereof, comprising the step of injecting into the vitreous of the subject an amount of a naked antisense oligonucleotide targeting a gene encoding ABCA4, wherein the antisense oligonucleotide comprises a sequence that is complementary to a splice donor site, splice acceptor site, or a branch site within the pre-mRNA of the ABCA4 gene, wherein the naked antisense oligonucleotide performs antisense oligonucleotide-mediated exon skipping in the pre-mRNA from the ABCA4 gene which mutation causes Stargardt disease in the nucleus of a photoreceptor cell of the subject, and wherein the antisense oligonucleotide is chronically administered by intravitreal injections at least 10 days apart.
6. The method of claim 5 , wherein the naked antisense oligonucleotide performs antisense oligonucleotide-mediated exon skipping in the nucleus of a photoreceptor cell of the subject.
7. The method of claim 5 , wherein the naked antisense oligonucleotide is selected from the group consisting of oligodeoxyribonucleotides, oligoribonucleotides, Locked Nucleic Acid (LNA) oligonucleotides, morpholinos oligonucleotides, tricyclo-DNA-antisense oligonucleotides, U7- or U1-mediated antisense oligonucleotides, peptide-conjugated, nanoparticle-complexed antisense oligonucleotides, 2′-O-Me RNA/ENA chimera oligonucleotides, and 2′-O-methyl-phosphorothioate oligonucleotides.
8. The method of claim 5 , wherein the antisense oligonucleotide is 10-50 nucleotides in length.
9. The method of claim 5 , wherein the antisense oligonucleotide is chronically administered by intravitreal injections at least one month apart.